ClinicalTrials.gg

Choroidal Neovascularization clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 214 studies for Choroidal Neovascularization across more than 10 countries. 12 are recruiting or about to start. 95 of them are mainly about Choroidal Neovascularization (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-17. Counting its narrower condition Polypoidal Choroidal Vasculopathy too: 261 studies, 19 open.

Status

Completed
142
Terminated
23
Status unknown
21
Withdrawn
9
Active, not recruiting
7
Not yet recruiting
6

Phase

Phase 2
62
Phase 3
49
Phase 1
35
Phase 4
24

Where

United States
88
France
26
Italy
26
Germany
19
Spain
18
Australia
16

Who develops what

Add Choroidal Neovascularization to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 2 programs from 2 companies, 0 with this as their studies’ main aim; 1 with a live phase 3 study; 0 primary completions in the next 12 months.

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
afliberceptRecent, repeated
Evidence
  • NCT07798375 · Everest Medicines (China) Co.,Ltd. · Phase 2 · live · comparator · “Aflibercept (Eylea)” · registered Aug 2026
  • NCT07496567 · Merck & Co., Inc · Phase 3 · live · comparator · “Aflibercept” · registered Mar 2026
  • NCT07440225 · Merck & Co., Inc · Phase 3 · live · comparator · “Aflibercept” · registered Feb 2026
  • NCT05407636 · AbbVie · Phase 3 · live · comparator · “Aflibercept (EYLEA®)” · registered Jan 2022
  • NCT04005352 · Novartis · Phase 3 · comparator · “Aflibercept 2 mg” · registered Jul 2019
Regeneron Pharmaceuticals28% of its industry studiesUS: Regeneron Pharmaceuticals (FDA 2011) + 5 othersEU: Bayer (EMA 2012) + 12 others34 studies

1 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

The 2 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (0)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

None in the next 12 months.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Choroidal Neovascularization studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Angiogenesis inhibitors 2 open · Tyrosine kinase inhibitors (TKIs) 7 · Corticosteroids 7 · mTOR inhibitors 4

Coming up

4studies finish main data collection within a year1 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

All 4, phase 3 first

Who these studies take

Of the 6 Choroidal Neovascularization studies recruiting now, 4 (67%) set no upper age limit and 0 (0%) stop at 75 or younger. 0 (0%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 0 (0%) take healthy volunteers.

Recruiting studies that take each age, of 6
AgeWomenMen
100 (0%)0 (0%)
182 (33%)2 (33%)
302 (33%)2 (33%)
402 (33%)2 (33%)
506 (100%)6 (100%)
656 (100%)6 (100%)
756 (100%)6 (100%)
856 (100%)6 (100%)

Across all 214 studies, recruiting or not: 7% stop at 75 or younger and 5% at 65; 10% take children; 0% are for women only and <1% for men only; 9% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Choroidal Neovascularization studies take

Of 15 phase 3 interventional studies under Choroidal Neovascularization, half reached primary completion within 27 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 327 mo23–35 · 15 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

Studies

Recruiting first, then most recently updated. Showing 50 of 214. Browse all 214 → or search them.